Arcus Biosciences (RCUS) Stock Forecast, Price & News

Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

Is Arcus Biosciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences or view top-rated stocks.

Are investors shorting Arcus Biosciences?

Arcus Biosciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 8,460,000 shares, an increase of 48.2% from the March 31st total of 5,710,000 shares. Based on an average daily volume of 991,900 shares, the short-interest ratio is currently 8.5 days. Approximately 19.0% of the shares of the company are short sold.
View Arcus Biosciences' Short Interest.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arcus Biosciences.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings data on Monday, May, 9th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of $0.83 by $1.79. Arcus Biosciences had a trailing twelve-month return on equity of 8.25% and a net margin of 14.67%. During the same period in the prior year, the company posted ($1.08) earnings per share.
View Arcus Biosciences' earnings history.

What price target have analysts set for RCUS?

6 Wall Street analysts have issued 1-year target prices for Arcus Biosciences' shares. Their forecasts range from $42.00 to $100.00. On average, they anticipate Arcus Biosciences' stock price to reach $60.86 in the next year. This suggests a possible upside of 221.7% from the stock's current price.
View analysts' price targets for Arcus Biosciences or view top-rated stocks among Wall Street analysts.

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:

• Dr. Terry J. Rosen Ph.D., Co-Founder, Chairman & CEO (Age 62, Pay $932.12k)
• Dr. Juan Carlos Jaen Ph.D., Co-Founder, Pres & Director (Age 64, Pay $838.2k)
• Mr. Robert C. Goeltz II, Principal Financial & Accounting Officer and CFO (Age 49, Pay $613.2k) (LinkedIn Profile)
• Ms. Jennifer Jarrett M.B.A., COO & Director (Age 51, Pay $828.2k) (LinkedIn Profile)
• Ms. Carolyn C. Tang J.D., Gen. Counsel & Corp. Sec. (Age 43, Pay $603.2k) (LinkedIn Profile)
• Dr. Stephen Young Ph.D., Sr. VP of Technology & Quantitative Biology (Age 53)
• Dr. Jonathan Yingling Ph.D., Chief Scientific Officer (Age 53)
• Ms. Katherine Bock, VP of Investor Relations & Corp. Strategy
• Holli Kolkey, VP of Corp. Communications
• Ms. Yvonne Gehring, VP of HR & Operations

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arcus Biosciences' key competitors?

Some companies that are related to Arcus Biosciences include Acerus Pharmaceuticals (ASPCF), Hypera (HYPMY), Perrigo (PRGO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Galapagos (GLPG), Cerevel Therapeutics (CERE), Zai Lab (ZLAB), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), CureVac (CVAC), Blueprint Medicines (BPMC) and Cytokinetics (CYTK).
View all of RCUS's competitors.

What other stocks do shareholders of Arcus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.77%), Vanguard Group Inc. (4.90%), State Street Corp (3.83%), Decheng Capital Management III Cayman LLC (1.21%), TimesSquare Capital Management LLC (1.15%) and Northern Trust Corp (0.84%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences.

Which institutional investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, TimesSquare Capital Management LLC, First Trust Advisors LP, Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, Northern Trust Corp, Federated Hermes Inc., and Metropolitan Life Insurance Co NY. Company insiders that have sold Arcus Biosciences company stock in the last year include Carolyn C Tang, Jennifer Jarrett, Juan C Jaen, Robert C Goeltz II, Terry J Rosen, and William Grossman.
View insider buying and selling activity for Arcus Biosciences or view top insider-selling stocks.

Which institutional investors are buying Arcus Biosciences stock?

RCUS stock was acquired by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, State Street Corp, Dimensional Fund Advisors LP, UBS Group AG, Sessa Capital IM L.P., Goldman Sachs Group Inc., Invesco Ltd., and Granahan Investment Management LLC. Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Kathryn E Falberg, Robert C Goeltz II, William Grossman, and Yasunori Kaneko.
View insider buying and selling activity for Arcus Biosciences or or view top insider-buying stocks.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $18.92.

How much money does Arcus Biosciences make?

Arcus Biosciences has a market capitalization of $1.36 billion and generates $382.88 million in revenue each year. The company earns $52.83 million in net income (profit) each year or $0.549990 on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 366 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at (510) 694-6200 or via email at [email protected].